TD Cowen Reiterates a Buy Rating on Legend Biotech Corporation (LEGN)

Legend Biotech Corporation (NASDAQ:LEGN) is one of the best biotech stocks with high potential. On October 3, TD Cowen analyst Yaron Werber reiterated a Buy rating on Legend Biotech Corporation (NASDAQ:LEGN), keeping the price target at $62.00. Legend Biotech Corporation (LEGN): Among Takeover Rumors Hedge Funds Are Buying The analyst supported the optimistic rating with the company’s future growth potential and strategic positioning. He stated that while Legend Biotech Corporation (NASDAQ:LEGN) is expe ...